logo-loader
viewVolitionRx

VolitionRx releases prostate cancer data, moving towards larger trials

VolitionRx Limited (NYSE:VNRX) CEO Cameron Reynolds speaks to Proactive at the MicroCap Conference in New York.

Reynolds commented on recent preliminary data from a prospective study on Volition's Nu.Q™ assays to diagnose men with high-grade prostate cancer.

He says If these results are validated in larger trials, they will present a potentially significant new market opportunity

Quick facts: VolitionRx

Price: 3.67 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $169.65 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRX encouraged by early data on its Nu.QTM blood test as potential...

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds tells Proactive's Andrew Scott they've been investigating how its Nu.QTM platform might be clinically useful as either a diagnostic or prognostic tool for COVID-19 and that they've been encouraged by some of the early data. He says...

on 05/08/2020

2 min read